ArticleHaematologica2014
Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats.
Article in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials.BMC nephrology · 2024Pooled it
- Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.British journal of clinical pharmacology · 2019Trial
- Anemia of Inflammation.Advances in experimental medicine and biology · 2025Review
- Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment.Nutrients · 2021Review
- Prevalence of Anemia in Pediatric Patients According to Asthma Control: Propensity Score Analysis.Journal of asthma and allergy · 2021Article
- Article
- Atopic Disease and Anemia in Korean Patients: Cross-Sectional Study with Propensity Score Analysis.International journal of environmental research and public health · 2020Article
- Anemia of inflammation.Blood · 2019Review
- Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Hepcidin Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Correction of Anemia in Chronic Kidney Disease WithFrontiers in pharmacology · 2018Article
- Iron in the Tumor Microenvironment-Connecting the Dots.Frontiers in oncology · 2018Review
- Establishment and characterization of a novel murine model of pancreatic cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2017Article
- Role of hepcidin-ferroportin axis in the pathophysiology, diagnosis, and treatment of anemia of chronic inflammation.Hemodialysis international. International Symposium on Home Hemodialysis · 2017Review
- Anaemia of Chronic Disease: An In-Depth Review.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2017Review
- Iron deficiency or anemia of inflammation? : Differential diagnosis and mechanisms of anemia of inflammation.Wiener medizinische Wochenschrift (1946) · 2016Review
- Hepcidin regulation in the anemia of inflammation.Current opinion in hematology · 2016Review
- Mice with hepcidin-resistant ferroportin accumulate iron in the retina.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016Article
- [Hepcidin for iron homeostasis and target therapy in ironrelated disorders].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation.Haematologica · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia of chronic disease is a multifactorial disorder, resulting mainly from inflammation-driven reticuloendothelial iron retention, impaired erythropoiesis, and reduced biological activity of erythropoietin. Erythropoiesis-stimulating agents have been used for the treatment of anemia of chronic disease, although with varying response rates and potential adverse effects. Serum concentrations of hepcidin, a key regulator of iron homeostasis, are increased in patients with anemia of chronic disease and linked to the pathogenesis of this disease, because hepcidin blocks cellular iron egress, thus limiting availability of iron for erythropoiesis. We tested whether serum hepcidin levels can predict and affect the therapeutic efficacy of erythropoiesis-stimulating agent treatment using a well-established rat model of anemia of chronic disease. We found that high pre-treatment hepcidin levels correlated with an impaired hematologic response to an erythropoiesis-stimulating agent in rats with anemia of chronic disease. Combined treatment with an erythropoiesis-stimulating agent and an inhibitor of hepcidin expression, LDN-193189, significantly reduced serum hepcidin levels, mobilized iron from tissue stores, increased serum iron levels and improved hemoglobin levels more effectively than did the erythropoiesis-stimulating agent or LDN-193189 monotherapy. In parallel, both the erythropoiesis-stimulating agent and erythropoiesis-stimulating agent/LDN-193189 combined reduced the expression of cytokines known to inhibit erythropoiesis. We conclude that serum hepcidin levels can predict the hematologic responsiveness to erythropoiesis-stimulating agent therapy in anemia of chronic disease. Pharmacological inhibition of hepcidin formation improves the erythropoiesis-stimulating agent's therapeutic efficacy, which may favor a reduction of erythropoiesis-stimulating agent dosages, costs and side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.